Videos

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, describes oncoplastic surgery.

As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.

Hyman B. Muss, MD, discusses optimizing the administration of endocrine therapies with or without mTOR inhibitors for patients with HR-positive metastatic breast cancer

Eribulin mesylate (Halaven) proved safe and effective as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer in final phase II clinical trial results

Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses markers of resistance in patients with HER2+ breast cancer.

For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, describes research involving the ESR1 gene mutation in breast cancer.

Using blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.

As PARP inhibitors continue to emerge as a novel class of anticancer agents, BMN 673 has entered late-stage clinical development as a treatment for patients with locally advanced or metastatic breast cancer whose tumors test positive for germline BRCA1/2 mutations.

High-tech eyewear could soon help surgeons remove tumors from patients with breast cancer or melanoma by allowing them to see the margins of tumors more accurately when a dye is used to fluoresce a tumor's borders.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

Dawn L. Hershman, MD, MS, describes the HOPE study, which looked at the effect of exercise versus usual care on aromatase inhibitor-associated arthralgias (joint pain) in women with breast cancer.

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Final results from the phase II PALOMA-1 trial continue to support the dramatic efficacy of palbociclib plus letrozole in postmenopausal patients with locally advanced or newly diagnosed estrogen receptor ER-positive, HER2-negative metastatic breast cancer.

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the rationale behind the phase III PENELOPE trial.